MUC16 and ovarian cancer: Proteolytic cleavage of MUC16 releases CA-125 into the bloodstream, retaining the membrane-associated C-terminal on the cell surface; CA-125, a biomarker for ovarian cancer (31), is targeted by emerging therapies such as Chimeric Antigen Receptor (CAR) T cells (32) and antibody-drug conjugates (ADCs) (33).